Abstract
AIMS—To identify all young people prescribed growth hormone in the UK as of 1 October 1998 and to determine their age, sex, and the indication for therapy. METHODS—Cross sectional national postal audit through members of the British Society for Paediatric Endocrinology and Diabetes (BSPED) and other paediatricians identified as potential prescribers of growth hormone. Main outcome measures were age, sex, and numbers of children receiving growth hormone by diagnostic category, analysed throughout the UK and by NHS region. RESULTS—A total of 3228 children (aged 0.3 to 23.9 years) receiving growth hormone were identified by contacting 171 paediatricians (149 BSPED members). Of these, 2395 (74%) were identified who were under 16 years—representing 19.8/100 000 children in that age range in the UK—and in whom full data concerning diagnostic category were available. In the under 16s, there were 1209 (50.4%) boys and 1186 (49.6%) girls (excluding the 477 girls with Turner's syndrome: 63% boys and 37% girls). A total of 78% of the prescriptions were for licensed indications (primary and secondary growth hormone deficiency, Turner's syndrome, and chronic renal disease); 22% were for unlicensed indications (intrauterine growth restriction, bony dysplasia, Noonan syndrome, and other "short normals"). These proportions are similar to those reported in previous audits and by postmarketing surveillance from Pharmacia & Upjohn Ltd in the year 2000. Patterns of treatment were relatively uniform between regions. CONCLUSIONS—A national audit of UK growth hormone prescription indicates uniform prescribing practice between regions, low levels of prescription beyond licensed indications, and stable patterns of prescribing practice over the past two years.
Full Text
The Full Text of this article is available as a PDF (81.2 KB).
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Brown P., Preece M. A., Will R. G. "Friendly fire" in medicine: hormones, homografts, and Creutzfeldt-Jakob disease. Lancet. 1992 Jul 4;340(8810):24–27. doi: 10.1016/0140-6736(92)92431-e. [DOI] [PubMed] [Google Scholar]
- Flodh H. Human growth hormone produced with recombinant DNA technology: development and production. Acta Paediatr Scand Suppl. 1986;325:1–9. doi: 10.1111/j.1651-2227.1986.tb10356.x. [DOI] [PubMed] [Google Scholar]
- Herber S. M., Milner R. D. When are we diagnosing growth hormone deficiency? Arch Dis Child. 1986 Feb;61(2):110–112. doi: 10.1136/adc.61.2.110. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Lindsay R., Feldkamp M., Harris D., Robertson J., Rallison M. Utah Growth Study: growth standards and the prevalence of growth hormone deficiency. J Pediatr. 1994 Jul;125(1):29–35. doi: 10.1016/s0022-3476(94)70117-2. [DOI] [PubMed] [Google Scholar]
- Milner R. D., Russell-Fraser T., Brook C. G., Cotes P. M., Farquhar J. W., Parkin J. M., Preece M. A., Snodgrass G. J., Mason A. S., Tanner J. M. Experience with human growth hormone in Great Britain: the report of the MRC Working Party. Clin Endocrinol (Oxf) 1979 Jul;11(1):15–38. doi: 10.1111/j.1365-2265.1979.tb03043.x. [DOI] [PubMed] [Google Scholar]
- Paterson W. F., Donaldson M. D., Greene S. A., Kelnar C. J., Smail P. J. The boom that never was: results of a 10 year audit of paediatric growth hormone prescribing in Scotland. Health Bull (Edinb) 2000 Nov;58(6):457–466. [PubMed] [Google Scholar]
- Price D. A., Johnston D. I., Betts P. R., Buckler J. M., Donaldson M. D. Biosynthetic human growth hormone treatment in the UK: an audit of current practice. Kabi Pharmacia International Growth Study. Arch Dis Child. 1994 Sep;71(3):266–271. doi: 10.1136/adc.71.3.266. [DOI] [PMC free article] [PubMed] [Google Scholar]
- RABEN M. S. Treatment of a pituitary dwarf with human growth hormone. J Clin Endocrinol Metab. 1958 Aug;18(8):901–903. doi: 10.1210/jcem-18-8-901. [DOI] [PubMed] [Google Scholar]